Webinare

Wir stellen vor Revvity – Die Grenzen des menschlichen Potenzials durch Wissenschaft erweitern.
Alle Produkte und Dienstleistungen, die zuvor mit Oxford Immunotec verbunden waren, sind jetzt Teil von Revvity.

Erfahren Sie mehr

Webinaraufzeichnungen

Verfolgen Sie Aufzeichnungen von Webinaren, die Oxford Immunotec veranstaltet und gesponsert hat. Klicken Sie auf die Links unten, um die Webinare zu sehen:

Vorteile von TB-IGRA-Tests mit ELISPOT – jetzt von der globalen Initiative für TB-Arzneimittelbeschaffung (GDF)

Webinar ansehen

Die richtige TB-Diagnostik für Immunsupprimierte wählen

Webinar ansehen

Doppelepidemie von TB und COVID-19: Herausforderungen und Kontroversen

Webinar ansehen

Erfahren Sie mehr über den
T-SPOT.TB-Test.

Kontaktieren Sie uns!

Verweise

Global tuberculosis report 2020. Geneva: World Health Organization; 2020. CC BY-NC-SA 3.0 IGO
Oxford Immunotec. T-SPOT.TB Package Insert PI-TB-IVD-UK-v3. Abingdon, UK. 2016.
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American ThoracicSociety/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. Published online December 8, 2016:ciw694. doi:10.1093/cid/ciw694
Wong SH, Gao Q, Tsoi KKF, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71:64–72.
Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5:1-25.
WHO End TB Strategy. World Health Organization. Published September 8, 2015. Accessed November 12, 2020.
Wrighton-Smith P, Sneed L, Humphrey F, Tao X, Bernacki E. Screening health care workers with interferon-γ release assay versus tuberculin skin test: Impact on costs and adherence to testing (the SWITCH study). J Occupational & Environmental Med. 2012;54(7):806-815
Oxford Immunotec. T-Cell Xtend Package Insert. PI-TT.610-UK-V6. Abingdon, UK. 2017.
Tuberculosis (TB). Centers for Disease Control and Prevention. CDC Tuberculosis. Published December 31, 2018. Accessed November 12, 2020.
Diabetes Fact Sheets. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed November 12, 2020.
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30
RA Facts: What are the latest statistics on Rheumatoid Arthritis? Rheumatoid Arthritis Support Network. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/. Accessed November 12, 2020.
The Global HIV/AIDS epidemic. HIV.gov. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics. Accessed November 12, 2020.
Chronic Kidney Disease (CKD) Symptoms and causes. National Kidney Foundation. https://www.kidney.org/atoz/content/about-chronic-kidney-disease. Accessed November 12, 2020.
TB comorbidities and risk factors. World Health Organization. https://www.who.int/tb/areas-of-work/treatment/risk-factors/en/. Accessed November 12, 2020.
Lai CC, Tan CK, et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. J Microbiol Immunol Infect. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.
Redelman-Sidi G, Sepkowitz KA. Interferon-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013; 188:422-431. 2012/12/25. DOI: 10.1164/rccm.201209-1621CI.
US – Take on TB. Centers for Disease Control and Prevention. CDC Take on Tuberculosis Infographic. Accessed January 8, 2020.
Signs & Symptoms. Centers for Disease Control and Prevention. CDC Tuberculosis Signs and Symptoms. Published March 17, 2016. Accessed January 8, 2020.
Exposure to TB. Centers for Disease Control and Prevention. CDC Exposure to TB. Published March 21, 2016. Accessed January 8, 2020.
TB Risk Factors. Centers for Disease Control and Prevention. CDC TB Risk Factors. Published March 18, 2016. Accessed January 8, 2020.
Huebner R, Schein M, Bass J. The tuberculin skin test. Clin Infect Dis. 1993;968-975.
Treatment for TB Disease. Centers for Disease Control and Prevention. CDC Treatment for TB Disease. Published April 5, 2016. Accessed January 8, 2020.

Webinare

Webinaraufzeichnungen

Verfolgen Sie Aufzeichnungen von Webinaren, die Oxford Immunotec veranstaltet und gesponsert hat. Klicken Sie auf die Links unten, um die Webinare zu sehen:

Vorteile von TB-IGRA-Tests mit ELISPOT – jetzt von der globalen Initiative für TB-Arzneimittelbeschaffung (GDF)

Die richtige TB-Diagnostik für Immunsupprimierte wählen

Doppelepidemie von TB und COVID-19: Herausforderungen und Kontroversen

Erfahren Sie mehr über den T-SPOT.TB-Test.

Erfahren Sie mehr über den
T-SPOT.TB-Test.